...
首页> 外文期刊>Biotechnology Progress >Promoting α-Secretase Cleavage of Beta-Amyloid with Engineered Proteolytic Antibody Fragments
【24h】

Promoting α-Secretase Cleavage of Beta-Amyloid with Engineered Proteolytic Antibody Fragments

机译:工程蛋白水解抗体片段促进β-淀粉样蛋白的α-分泌酶裂解。

获取原文
获取原文并翻译 | 示例
           

摘要

Deposition of beta-amyloid (Aβ) is considered as an important early event in the pathogenesis of Alzheimer's Disease (AD),and reduction of Aβ levels by various therapeutic approaches is actively being pursued. A potentially non-inflammatory approach to facilitate clearance and reduce toxicity is to hydrolyze Aβ at its α-secretase site. We have previously identified a light chain fragment,mkl8,with α-secretase-like catalytic activity,producing the 1-16 and 17-40 amino acid fragments of Aβ40 as primary products,although hydrolysis is also observed following other lysine and arginine residues. To improve the specific activity of the recombinant antibody by affinity maturation,we constructed a single chain variable fragment (scFv) library containing a randomized CDR3 heavy chain region. A biotinylated covalently reactive analog mimicking α-secretase site cleavage was synthesized,immobilized on streptavidin beads,and used to select yeast surface expressed scFvs with increased specificity for Aβ. After two rounds of selection against the analog,yeast cells were individually screened for proteolytic activity towards an internally quenched fluoro-genic substrate that contains the α-secretase site of Aβ. From 750 clones screened,the two clones with the highest increase in proteolytic activity compared to the parent mk18 were selected for further study. Kinetic analyses using purified soluble scFvs showed a 3- and 6-fold increase in catalytic activity (k_(cat)/K_M) toward the synthetic Aβ substrate compared to the original scFv primarily due to an expected decrease in K_M rather than an increase in k_(cat). This affinity maturation strategy can be used to select for scFvs with increased catalytic specificity for Aβ. These proteolytic scFvs have potential therapeutic applications for AD by decreasing soluble Aβ levels in vivo.
机译:β-淀粉样蛋白(Aβ)的沉积被认为是阿尔茨海默病(AD)发病机理中的重要早期事件,并且通过各种治疗方法积极地降低Aβ水平。促进清除并降低毒性的潜在非炎性方法是在其α-分泌酶位点水解Aβ。我们先前已经鉴定出具有α-分泌酶样催化活性的轻链片段,mkl8,产生Aβ40的1-16和17-40个氨基酸片段作为主要产物,尽管在其他赖氨酸和精氨酸残基之后也观察到水解。为了通过亲和力成熟来提高重组抗体的比活性,我们构建了包含随机CDR3重链区的单链可变片段(scFv)库。合成了模仿α-分泌酶位点裂解的生物素化共价反应类似物,固定在链霉亲和素珠上,并用于选择对Aβ特异性提高的酵母表面表达的scFv。经过两轮针对类似物的选择后,分别筛选了酵母细胞针对内部淬灭的荧光底物的蛋白水解活性,该底物含有Aβ的α-分泌酶位点。从筛选的750个克隆中,选择与亲本mk18相比蛋白水解活性增加最高的两个克隆进行进一步研究。使用纯化的可溶性scFv进行的动力学分析表明,与原始scFv相比,对合成Aβ底物的催化活性(k_(cat)/ K_M)分别提高了3倍和6倍,这主要是由于预期的K_M降低而不是k_M升高(猫)。该亲和力成熟策略可用于选择对Aβ具有增加的催化特异性的scFv。这些蛋白水解scFv通过降低体内可溶性Aβ水平而具有潜在的AD治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号